RSTP1000

RSTP1000 is an oral psilocybin investigational drug being developed by Reset Pharma as a psychedelic-assisted therapy for demoralization syndrome in patients with cancer. It employs psilocybin, a prodrug rapidly converted to psilocin, which acts as a non‑selective serotonin receptor agonist with prominent activity at 5‑HT2A receptors, producing acute alterations in perception and cognition that can translate into rapid and sustained reductions in anxiety, depression, and existential distress when combined with structured psychotherapy. Reset Pharma positions RSTP1000 as a supportive therapy to improve morale and psychological well‑being in oncology patients, where no approved treatments for demoralization syndrome currently exist.[1][4][5][7][9][10]